Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of shortened up-dosing with Alutard SQ
2017-000971-97Phase 2Completed
- Sponsor
- ALK-Abelló
- Start
- Jun 2017
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial of alutard-sq in allergic rhinoconjunctivitis (ARC) (2 arms), sponsored by ALK-Abelló. Primary endpoint: Number of IMP-related treatment emergent adverse events (TEAEs) per subject. Started Jun 2017; status: completed.
02
Drugs
alutard-sq
03
Conditions
allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on 2017-000971-97.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000971-97.